• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effectiveness and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: Protocol for systematic review and meta-analysis.中药治疗非酒精性脂肪性肝病的有效性和安全性:系统评价与Meta分析方案
Medicine (Baltimore). 2020 Jun 19;99(25):e20699. doi: 10.1097/MD.0000000000020699.
2
Effectiveness and safety of traditional Chinese medicines for pulmonary heart disease: A protocol for systematic review and meta-analysis.中药治疗肺心病的有效性和安全性:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Jan 8;100(1):e24131. doi: 10.1097/MD.0000000000024131.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Acupuncture and Moxibustion for restless legs syndrome: A systematic review and meta-analysis protocol.针灸治疗不宁腿综合征:一项系统评价与荟萃分析方案
Medicine (Baltimore). 2020 Jan;99(4):e18827. doi: 10.1097/MD.0000000000018827.
5
Effectiveness and safety of traditional Chinese medicine in the treatment of senile hypotension: A protocol for systematic review and meta-analysis.中药治疗老年低血压的有效性和安全性:一项系统评价与Meta分析方案
Medicine (Baltimore). 2021 Apr 23;100(16):e25385. doi: 10.1097/MD.0000000000025385.
6
Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews.用于非酒精性脂肪性肝病的中药方剂:系统评价概述
World J Clin Cases. 2021 Jan 6;9(1):102-117. doi: 10.12998/wjcc.v9.i1.102.
7
Efficacy of traditional Chinese medicine-based clearing heat and laxative method against nonalcoholic fatty liver disease: A systematic review and meta-analysis.基于中医清热泻下法治疗非酒精性脂肪性肝病的疗效:一项系统评价与Meta分析
Medicine (Baltimore). 2025 Apr 25;104(17):e42189. doi: 10.1097/MD.0000000000042189.
8
Acupuncture combined with Chinese herbal medicine on non-alcoholic fatty liver disease: A protocol for systematic review and meta-analysis.针灸结合中药治疗非酒精性脂肪性肝病的系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Dec 23;100(51):e28083. doi: 10.1097/MD.0000000000028083.
9
The effectiveness and safety of Chinese medicines for the treatment of uveitis: A protocol for systematic review and meta-analysis.中药治疗葡萄膜炎的有效性和安全性:系统评价与Meta分析方案
Medicine (Baltimore). 2020 Jun 26;99(26):e20766. doi: 10.1097/MD.0000000000020766.
10
Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis.血府逐瘀汤治疗非酒精性脂肪性肝病的系统评价和 Meta 分析方案。
Medicine (Baltimore). 2021 May 14;100(19):e25358. doi: 10.1097/MD.0000000000025358.

引用本文的文献

1
Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.基于 RNA 测序和网络药理学的整合策略,探索参术降脂方治疗非酒精性脂肪性肝病大鼠的作用机制。
Pharm Biol. 2022 Dec;60(1):1819-1838. doi: 10.1080/13880209.2022.2106250.

本文引用的文献

1
Utilization of traditional and complementary medicine in Indonesia: Results of a national survey in 2014-15.印度尼西亚传统和补充医学的利用:2014-15 年全国调查结果。
Complement Ther Clin Pract. 2018 Nov;33:156-163. doi: 10.1016/j.ctcp.2018.10.006. Epub 2018 Oct 10.
2
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.非酒精性脂肪性肝炎(NASH)的未来药物治疗:2期和3期试验综述
J Clin Transl Hepatol. 2018 Sep 28;6(3):264-275. doi: 10.14218/JCTH.2017.00056. Epub 2018 Jun 28.
3
Current and future pharmacological therapies for NAFLD/NASH.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的当前和未来药理学治疗方法。
J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16.
4
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担:趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
5
New trends on obesity and NAFLD in Asia.亚洲肥胖和非酒精性脂肪性肝病的新趋势。
J Hepatol. 2017 Oct;67(4):862-873. doi: 10.1016/j.jhep.2017.06.003. Epub 2017 Jun 19.
6
Therapies in non-alcoholic steatohepatitis (NASH).非酒精性脂肪性肝炎(NASH)的治疗方法。
Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):97-103. doi: 10.1111/liv.13302.
7
Nonalcoholic steatohepatitis (NASH) drugs market.非酒精性脂肪性肝炎(NASH)药物市场。
Nat Rev Drug Discov. 2016 Nov 3;15(11):745-746. doi: 10.1038/nrd.2016.188.
8
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.依洛前列素,一种过氧化物酶体增殖物激活受体-α和-δ激动剂,可在不加重肝纤维化的情况下诱导非酒精性脂肪性肝炎消退。
Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.
9
Prevalence of Nonalcoholic Fatty Liver Disease and Economy.非酒精性脂肪性肝病的患病率与经济状况
Dig Dis Sci. 2015 Nov;60(11):3194-202. doi: 10.1007/s10620-015-3728-3. Epub 2015 May 28.
10
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.肥胖症手术可减轻病态肥胖患者非酒精性脂肪性肝炎的特征。
Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6. doi: 10.1053/j.gastro.2015.04.014. Epub 2015 Apr 25.

中药治疗非酒精性脂肪性肝病的有效性和安全性:系统评价与Meta分析方案

Effectiveness and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: Protocol for systematic review and meta-analysis.

作者信息

Qin Manman, Yuan Fuqiang, Ren Jiankun, Chi Zhenhai

机构信息

Jiangxi University of Traditional Chinese Medicine, Wanli District, Nanchang, Jiangxi.

Henan Vocational College of Nursing, Anyang, Henan.

出版信息

Medicine (Baltimore). 2020 Jun 19;99(25):e20699. doi: 10.1097/MD.0000000000020699.

DOI:10.1097/MD.0000000000020699
PMID:32569201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7310736/
Abstract

BACKGROUND

Previous reviews indicate that the effect of Traditional Chinese medicines (TCM) on non-alcoholic fatty liver disease (NAFLD) remains uncertainty. The study results published in the past 8 years may change this situation, but there is no updated systematic review. Therefore, we designed this study to systematically evaluate the effectiveness and safety of TCM in the treatment of NAFLD.

METHODS AND ANALYSIS

We will search nine online databases from inception to October 01 2019, and the language will not be restricted on included trials. Randomized controlled trials that included patients with NAFLD receiving TCM therapy versus a control group will be included. Two researcher will perform independently the selection of studies, risk of bias assessment and data extraction. We will use the RevMan V.5.2 software with fixed effects model or random effects model according to the heterogeneity test to conduct the data synthesis. We will present the dichotomous data and the continuous data with risk ratios with 95% CIs and weighted mean differences or standardized mean differences with 95% CIs. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system will be used to evaluate the evidence quality with low risk, unclear risk, and high risk.

RESULTS

This study will demonstrate an evidence-based review of TCM for NAFLD.

CONCLUSION

The study will provide clear evidence to assess the effectiveness and side effects of TCM for NAFLD.

摘要

背景

既往综述表明,中药对非酒精性脂肪性肝病(NAFLD)的疗效仍不确定。过去8年发表的研究结果可能会改变这种情况,但尚无更新的系统评价。因此,我们设计了本研究,以系统评价中药治疗NAFLD的有效性和安全性。

方法与分析

我们将检索9个在线数据库,检索时间从建库至2019年10月1日,纳入试验的语言不限。纳入将NAFLD患者接受中药治疗与对照组进行比较的随机对照试验。两名研究人员将独立进行研究筛选、偏倚风险评估和数据提取。我们将根据异质性检验,使用RevMan V.5.2软件采用固定效应模型或随机效应模型进行数据合成。我们将以风险比及95%置信区间呈现二分类数据,以加权均数差或标准化均数差及95%置信区间呈现连续数据。推荐分级评估、制定与评价(GRADE)系统将用于评估证据质量,分为低风险、风险不明确和高风险。

结果

本研究将展示对中药治疗NAFLD的循证综述。

结论

本研究将为评估中药治疗NAFLD的有效性和副作用提供明确证据。